- Home
- TYRA vs FTHY Comparison
TYRA vs FTHY Comparison
Compare TYRA & FTHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- FTHY
- Stock Information
- Founded
- TYRA 2018
- FTHY 2020
- Country
- TYRA United States
- FTHY United States
- Employees
- TYRA N/A
- FTHY N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- FTHY Investment Managers
- Sector
- TYRA Health Care
- FTHY Finance
- Exchange
- TYRA Nasdaq
- FTHY Nasdaq
- Market Cap
- TYRA 422.6M
- FTHY 500.1M
- IPO Year
- TYRA 2021
- FTHY N/A
- Fundamental
- Price
- TYRA $8.92
- FTHY $13.79
- Analyst Decision
- TYRA Strong Buy
- FTHY
- Analyst Count
- TYRA 6
- FTHY 0
- Target Price
- TYRA $30.50
- FTHY N/A
- AVG Volume (30 Days)
- TYRA 353.6K
- FTHY 176.7K
- Earning Date
- TYRA 05-08-2025
- FTHY 01-01-0001
- Dividend Yield
- TYRA N/A
- FTHY 10.93%
- EPS Growth
- TYRA N/A
- FTHY N/A
- EPS
- TYRA N/A
- FTHY N/A
- Revenue
- TYRA N/A
- FTHY N/A
- Revenue This Year
- TYRA N/A
- FTHY N/A
- Revenue Next Year
- TYRA N/A
- FTHY N/A
- P/E Ratio
- TYRA N/A
- FTHY N/A
- Revenue Growth
- TYRA N/A
- FTHY N/A
- 52 Week Low
- TYRA $6.42
- FTHY $12.66
- 52 Week High
- TYRA $29.60
- FTHY $14.74
- Technical
- Relative Strength Index (RSI)
- TYRA 45.95
- FTHY 43.00
- Support Level
- TYRA $8.23
- FTHY $13.49
- Resistance Level
- TYRA $8.80
- FTHY $13.99
- Average True Range (ATR)
- TYRA 0.70
- FTHY 0.35
- MACD
- TYRA 0.19
- FTHY 0.00
- Stochastic Oscillator
- TYRA 75.30
- FTHY 58.21
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income.